Catalent Stock

Catalent ROCE

Delisted·Dec 17, 2024

The Return on Capital Employed (ROCE) of Catalent (CTLT) as of Aug 5, 2026 is -20.78 %. In the previous year, Return on Capital Employed (ROCE) was -3.37 % — a change of 517.48% (lower).

ROCE

-20.78 %

YoY

517.48%

Last updated:

In 2026, Catalent's return on capital employed (ROCE) was -20.78 %, a 517.48% increase from the -3.37 % ROCE in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Catalent Stock analysis

What does Catalent do? Catalent Inc is a global leader in advanced active ingredients and medical products, as well as solutions for drug development and manufacturing. The company was founded in 1933 by the Schering brothers in the USA and has become one of the preferred partners in the pharmaceutical industry due to its innovation, flexibility, and reliability. Catalent's business model is based on providing high-quality services and products that contribute to improving human health. The company offers a wide range of solutions, from active ingredient development to drug formulation and manufacturing, clinical trials, and product packaging. Through this comprehensive offering, Catalent helps its customers accelerate their drug development and product launch. The company is divided into different business sectors with specialized solutions, including the manufacturing of biopharmaceuticals such as antibodies, cell therapies, and vaccines, as well as medical devices, active ingredient manufacturing, and pharmaceutical development and manufacturing. Catalent's services also include active ingredient development, assisting customers in all stages of drug development from identifying new active ingredients to optimizing production processes. The company specializes in formulating drugs into suitable delivery forms that ensure safe and effective use, offering a variety of oral, inhalable, and parenteral formulations. Catalent also provides clinical trials, testing the efficacy and safety of drugs in clinical trials. The company has state-of-the-art facilities and expertise to professionally and successfully support its customers in conducting clinical studies. Additionally, Catalent offers a wide range of packaging solutions, including glass bottles, plastic containers, aluminum tubes, and the finishing and packaging of finished drugs. The company has advanced production systems that enable quick and flexible packaging production in any desired size and shape. Overall, Catalent provides its customers with a comprehensive range of services and products that enable fast and effective drug development and market launch. The company's strong innovation and diverse range of expertise make it a preferred partner in the pharmaceutical industry. Catalent is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Catalent's Return on Capital Employed (ROCE)

Catalent's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Catalent's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Catalent's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Catalent’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Catalent stock

Return on Capital Employed (ROCE) of Catalent is -20.78 % in 2026.

Return on Capital Employed (ROCE) of Catalent changed from -3.37 % to -20.78 %, representing a 517.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Catalent since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Catalent with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Catalent

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Catalent